The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Fate Therapeutics Inc (NASDAQ: FATE) closed at $1.37 in the last session, up 9.60% from day before closing price of $1.25. In other words, the price has increased by $9.60 from its previous closing price. On the day, 3.66 million shares were traded. FATE stock price reached its highest trading level at $1.42 during the session, while it also had its lowest trading level at $1.26.
Ratios:
We take a closer look at FATE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.24.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 06 ’25 when Wolchko J Scott bought 113,178 shares for $0.93 per share.
Bressi Jerome Charles sold 5,980 shares of FATE for $9,269 on Jan 10 ’25. The insider now owns 270,203 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, TAHL CINDY, who serves as the insider of the company, sold 5,654 shares for $1.55 each. As a result, the insider received 8,764 and left with 336,707 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 157007488 and an Enterprise Value of -36801528. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.52 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at -2.7 whereas that against EBITDA is 0.208.
Stock Price History:
The Beta on a monthly basis for FATE is 1.87, which has changed by -0.68139535 over the last 52 weeks, in comparison to a change of 0.042615533 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $5.92, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 30.09%, while the 200-Day Moving Average is calculated to be -43.93%.
Shares Statistics:
According to the various share statistics, FATE traded on average about 2.30M shares per day over the past 3-months and 2565460 shares per day over the past 10 days. A total of 113.93M shares are outstanding, with a floating share count of 103.49M. Insiders hold about 9.70% of the company’s shares, while institutions hold 84.96% stake in the company. Shares short for FATE as of 1743379200 were 16374114 with a Short Ratio of 7.12, compared to 1740700800 on 13328335. Therefore, it implies a Short% of Shares Outstanding of 16374114 and a Short% of Float of 16.379999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for Fate Therapeutics Inc (FATE) reflects the collective analysis of 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.29 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.08 and -$1.72 for the fiscal current year, implying an average EPS of -$1.46. EPS for the following year is -$1.25, with 9.0 analysts recommending between -$0.73 and -$1.98.
